Image courtesy of Shutterstock
Researchers funded by the blood cancer charity Bloodwise analysed tumour samples from individual patients with diffuse large B-cell lymphoma (DLBCL), alongside cell line models and data on treatment response and survival.
DLBCL, an aggressive cancer affecting white blood cells, is diagnosed in around 5,000 people each year in the UK. There are several different subtypes of the disease, each of which differs in its response to chemotherapy.